SuperworthValion Bio VBIO
- Market cap
- $834.3K
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −1758.8%
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $282K−41% | $357K−13% | $334K−11% | $140K−13% | $126K−55% | $180K−50% | $70K−79% | $86K−39% | $146K+16% | n/a | n/a | n/a | |
| Cost of revenue | $174K−58% | $352K−4% | $167K−37% | $110K+10% | $82K−53% | $419K+19% | $20K−88% | $32K−71% | $291K+255% | n/a | n/a | n/a |
| Gross profit | $108K+71% | $5K−88% | $167K+48% | $30K−51% | $44K−59% | −$239K | $50K−70% | $54K+80% | −$145K | n/a | n/a | n/a |
| R&D | $337K−16% | $360K−17% | $256K−48% | $302K−36% | $422K+25% | $333K−8% | $335K+31% | $655K+117% | $858K+103% | n/a | $1.9M+453% | $2.7M+313% |
| SG&A | $1.5M−32% | $1.9M+1% | $1.4M−20% | $994K−42% | $1.1M−31% | $971K−49% | $1M−25% | $1M+3% | $1.5M+41% | n/a | $3.8M+263% | $3.7M+264% |
| −$1.8M−32% | −$2.2M−1% | −$1.5M−30% | −$1.3M−40% | −$1.4M−19% | −$1.5M−31% | −$1.4M−7% | −$1.7M+33% | −$2.5M+74% | n/a | −$5.6M+309% | −$6.4M+283% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | $0 | $0 | n/a | n/a | $648K | $691K |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$1.8M−32% | −$2.2M−1% | −$1.5M−30% | −$1.3M−40% | −$1.4M−19% | −$1.5M−34% | −$1.5M+1% | −$1.9M+53% | −$2.6M+81% | −$2.8M+93% | −$6.2M+313% | −$7.1M+268% |
| −$37.00−95% | n/a | −$428.75+63% | −$134.25−25% | −$5.75−85% | −$80.25 | −$63.00−85% | −$54.75−59% | n/a | n/a | n/a | n/a | |
| 47.6K+1129% | 58.6K+1412% | 3.5K−57% | 9.4K−21% | 247.6K+420% | 18.4K−69% | 23.9K+591% | 35.3K+274% | n/a | n/a | n/a | n/a |
EPS, diluted: 3 periods, Q4 FY21 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY21 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Valion Bio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| VBIOValion Bio | $834.3K | n/m | n/a | n/m | n/m | n/m | |
| NXTSNexentis Technologies | $761.8K | n/m | n/a | n/m | n/m | n/m | |
| LABTLakewood-Amedex Biotherapeutics | $734.6K | n/m | n/a | n/m | n/m | n/m | |
| JAGXJaguar Health | $702.9K | n/m | n/a | 0.0× | +136% | n/m | |
| DCOYDecoy Therapeutics | $635.5K | n/m | n/a | n/m | n/m | n/m | |
| SBFMSunshine Biopharma | $581.6K | n/m | n/a | 0.0× | −3% | −16.5% | |
| ARTLArtelo Biosciences | $1.3M | n/m | n/a | n/m | n/m | n/m | |
| LNAILunai Bioworks | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| GNPXGenprex | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| GOVXGeoVax Labs | $1.5M | n/m | n/a | n/a | −100% | n/a | |
| ONCOOnconetix | $1.7M | n/m | n/a | n/m | n/m | n/m | |
| Peer median | $1M | n/a | n/a | 0.0× | −3% | −16.5% |
More on Valion Bio
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .